These results identified METTL3 inhibition as a promising therapeutic strategy for AML treatment and demonstrated that targeting enzymes that modify RNA is a new approach promising anticancer therapy (Yankova et al., 2021). The gene discussed is METTL3; the disease is acute myeloid leukemia.